Response to sorafenib treatment in advanced metastatic thyroid cancer.

Fabian Pitoia

Journal: Arquivos brasileiros de endocrinologia e metabologia 2015;58(1):37-41

PMID: 24728162

Abstract

OBJECTIVE

To investigate the efficacy of sorafenib in progressive radioiodine resistant metastatic thyroid carcinoma.

SUBJECTS AND METHODS

Off-label observational study. Sorafenib 400 mg twice daily was evaluated. Therapy duration was 12 ± 3 months (range 6-16 months).

RESULTS

Eight patients were included (seven papillary, one insular variant). The eight patients meeting study criteria received sorafenib 400 mg orally twice a day until disease progression or unacceptable toxicity developed. One patient showed a partial response with tumor regression of -35%, six months after the beginning of the treatment; five patients exhibited stable disease and two patients had progressive disease and died. Thyroglobulin decreased within 4 weeks in all patients by 50% ± 23%. Adverse events: one patient had heart failure, and recovered after sorafenib withdrawal. However, she died five months later of sudden death.

CONCLUSION

These data suggest a possible role for sorafenib in the treatment of progressive metastatic DTC. Adverse event are usually manageable, but severe ones may appear and these patients should be strictly controlled.

Address: Private Office and Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina.

DOI: 10.1590/0004-2730000002839

Link outs

Free resources

Medical:

https://medlineplus.gov/thyroidcancer.html

Other Literature Sources:

https://scite.ai/reports/24728162

MeSH Terms: Aged, Antineoplastic Agents, Bone Neoplasms, Carcinoma, Papillary, Compassionate Use Trials, Female, Follow-Up Studies, Heart Failure, Humans, Iodine Radioisotopes, Lung Neoplasms, Male, Middle Aged, Niacinamide, Phenylurea Compounds, Response Evaluation Criteria in Solid Tumors, Sorafenib, Thyroglobulin, Thyroid Neoplasms, Treatment Outcome